Results 161 to 170 of about 2,739 (201)
Livestock Science, 2018 The aims of this study were to determine if the ewe’ vaginal bacterial load differs according to the stage of the oestrous cycle; and thus, if the stage of the oestrous cycle when intravaginal sponges (IS) used for oestrous synchronisation are inserted
Maria A Fiorentino, Rodolfo Ungerfeld
exaly +2 more sources
, 2008 The aim of this study was to compare effectiveness of antibiotic administration to intravaginal sponge before sponge insertion and investigate duration of sponge treatment for determining changes in the vaginal bacterial flora and fertility parameters.
Ozyurtlu, Nihat +2 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Toxic Shock Syndrome and the Vaginal Contraceptive Sponge
Obstetrical & Gynecological Survey, 1986Thirteen confirmed cases of toxic shock syndrome temporally related to use of the vaginal contraceptive sponge have been reported. The observed risk of toxic shock syndrome in sponge users may be elevated above estimated background rates, but this risk remains very low.
G, Faich +4 more
+5 more sources
Vaginal mucus from ewes treated with progestogen sponges affects quality of ram spermatozoa
Theriogenology, 2016 The use of intravaginal sponges (IS) to synchronize estrous onset in ewes provokes vaginitis, an increase in the vaginal bacterial load, and growth of bacterial species that are not present during spontaneous estrous behavior.
Maria A Fiorentino, Rodolfo Ungerfeld
exaly +2 more sources
Spermicides, HIV, and the Vaginal Sponge
JAMA: The Journal of the American Medical Association, 1992Despite the current epidemic of sexually transmitted human immunodeficiency virus (HIV) infection and other sexually transmitted diseases (STDs), prevention measures known to be effective are underutilized. Most prevention guidelines have appropriately emphasized abstinence, monogamy between uninfected partners, or condom use.
K M, Stone, H B, Peterson
openaire +3 more sources
Food and Drug Administration Approves Vaginal Sponge
Family Planning Perspectives, 1983On April 1 1983 the US Food and Drug Administration (FDA) approved a disposable vaginal sponge of soft polyurethane foam saturated with 1 gm of nonoxynol-9 as a nonprescription contraceptive offering 2 improvements over products already available: ability to leave in place up to 24 hours and no need for additional application of spermicide for ...
D, Kafka, R B, Gold
openaire +2 more sources
Metronidazole-containing vaginal sponges for the treatment of bacterial vaginosis
Advances in Contraception, 1986Currently, there is no FDA approved treatment for bacterial vaginosis (BV), although various oral dosages of metronidazole are used to treat this condition. A vaginal therapeutic sponge (VLI Corporation) that releases metronidazole over a 24 h use period has been developed for the treatment of BV. Each sponge contains 250 mg of metronidazole.
W E, Brenner, J R, Dingfelder
openaire +2 more sources
A System-Wide Initiative to Prevent Retained Vaginal Sponges
MCN: The American Journal of Maternal/Child Nursing, 2011As any perinatal nurse knows, retained vaginal sponges are an obstetrical and postpartum patient safety problem. As surgical sponge counts are not routine in some obstetrical units for vaginal births, our healthcare system chose to institute a rigorous process to eliminate retained sponges in all vaginal births.
Brenda A, Chagolla +3 more
openaire +2 more sources
Worldwide method effectiveness of the Today® vaginal contraceptive sponge
Advances in Contraception, 1985The Today vaginal contraceptive sponge is made of polyurethane and contains 1 gram of the spermicide nonoxynol-9. Following preclinical and phase I and II clinical trials, extensive worldwide phase III trials were conducted. These multiclinic trials were conducted according to a common protocol with regularly scheduled follow-up visits and examinations.
D A, McClure, D A, Edelman
openaire +2 more sources